Policy Statement

I. Suture button suspensionplasty for thumb carpometacarpal joint osteoarthritis is considered investigational.

NOTE: Refer to Appendix A to see the policy statement changes (if any) from the previous version.

Policy Guidelines

This CPT code may be used for Suture Button Suspensionplasty Fixation System for Thumb Carpometacarpal Osteoarthritis:

- 26989: Unlisted procedure, hands or fingers

Description

In the thumb, the most common site for arthritis to develop is in the joint at the base of the thumb, also known as the carpometacarpal (CMC) joint. Pain and functional limitations associated with symptomatic thumb CMC joint osteoarthritis, especially when pinching or gripping objects, can significantly interfere with quality of life. Surgery is indicated when conservative measures fail to provide sufficient relief and functional improvement. There is currently no consensus on the optimal surgical approach, but the most frequently used procedure is trapeziectomy with ligament reconstruction and tendon interposition (LRTI). Trapeziectomy using suture button suspensionplasty (SBS) is proposed as a less invasive alternative to trapeziectomy with LRTI.

Related Policies

- Synthetic Cartilage Implants for Joint Pain

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

Regulatory Status

In 2014, the CMC Mini TightRope System (Arthrex, Inc) was FDA cleared through the 510K process. Clearance was based on a determination that the device is substantially equivalent to the predicate device Arthrex Implant System (Mini TightRope). The CMC MiniTightRope system is
indicated for CMC joint arthroplasty as an adjunct in the suspension of the thumb metacarpal by providing stabilization at the base of the first and second metacarpal when the trapezium has been excised due to osteoarthritis.

Product code: HTN

**Rationale**

**Background**

**Thumb Carpometacarpal Joint Osteoarthritis**

In the thumb, the most common site for arthritis to develop is in the joint at the base of the thumb, also known as the carpometacarpal (CMC) joint. The incidence of CMC joint osteoarthritis is estimated to be 5% to 33% among adults in their 50s and 60s, and rises with age. It is more common in postmenopausal women. Pain and functional limitations, especially when pinching or gripping objects, can significantly interfere with quality of life.1

First-line treatment of CMC joint osteoarthritis includes non-surgical measures such as activity modifications, rest, hand orthosis, anti-inflammatory medications, physical therapy, and corticosteroid injections.2 Surgery is indicated when conservative treatment fails to provide sufficient relief and functional improvement. Although thumb CMC joint osteoarthritis is often staged using radiological classification systems (e.g., the Eaton-Littler classification), the severity of symptoms does not necessarily correspond to radiographic findings; therefore a decision to proceed to surgery is based on symptoms and degree of disability.3

Multiple surgical techniques to treat thumb CMC osteoarthritis have been developed but there is currently no consensus on the optimal approach.3,4,5 The most common surgical technique is removal of the trapezium bone at the base of the thumb (trapeziectomy). Trapeziectomy can be performed alone but is most commonly performed in conjunction with reconstruction of the ligament that holds the bones between the thumb and index finger together, and filling the space left behind by the removed trapezium with tendon harvested from the forearm to support the thumb. This procedure is known as trapeziectomy with ligament reconstruction and tendon interposition (LRTI). Either the flexor carpi radialis (FCR) tendon or abductor pollicis longus (APL) tendon is used in this procedure. Trapeziectomy using suture button suspensionplasty is proposed as a less invasive alternative to trapeziectomy with LRTI. Instead of using tendon to support the thumb, the procedure suspends the first metacarpal to the second using a strong suture material (fiberwire) passed through both bones. A button on each of the metacarpals is attached to either end of the suture to secure the bones in the correct pos.

**Literature Review**

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely
large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Promotion of greater diversity and inclusion in clinical research of historically marginalized groups (e.g., People of Color [African-American, Asian, Black, Latino and Native American]; LGBTQIA [Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual]; Women; and People with Disabilities [Physical and Invisible]) allows policy populations to be more reflective of and findings more applicable to our diverse members. While we also strive to use inclusive language related to these groups in our policies, use of gender-specific nouns (e.g., women, men, sisters, etc.) will continue when reflective of language used in publications describing study populations.

**Suture Button Suspensionplasty Fixation System for Thumb Carpometacarpal Joint Osteoarthritis**

**Clinical Context and Therapy Purpose**

The following PICO was used to select literature to inform this review.

**Populations**

The relevant population of interest is individuals with thumb carpometacarpal (CMC) joint osteoarthritis who have not responded to conservative treatment.

**Interventions**

The therapy being considered is suture button suspensionplasty with the CMC Mini TightRope System. Suture button suspensionplasty is intended to provide stabilization at the base of the first and second metacarpal following trapeziectomy for CMC joint osteoarthritis. The system suspends the first metacarpal to the second using suture material (fiberwire) passed through both bones. A button on each of the metacarpals is attached to either end of the suture to secure the bones in the correct position.

**Comparators**

Multiple surgical techniques to treat thumb CMC osteoarthritiis have been developed but there is currently no consensus on the optimal approach.\(^3,5\) The most common surgical technique is removal of the trapezium bone at the base of the thumb (trapeziectomy). Trapeziectomy can be performed alone but is most commonly performed in conjunction with reconstruction of the ligament that holds the bones between the thumb and index finger together and filling the space left behind by the removed trapezium with tendon harvested from the forearm to support the thumb. This procedure is known as trapeziectomy with ligament reconstruction and tendon interposition (LRTI).

**Outcomes**

The general outcomes of interest are symptoms, functional outcomes, and treatment-related morbidity.

The Disabilities of the Arm, Shoulder and Hand (DASH) and QuickDASH Questionnaires and the Visual Analog Scale for pain are patient-reported outcome measures commonly used to assess surgical treatment of thumb CRC osteoarthritis (Table 1).

There are no guidelines specific to the duration of follow-up to assess outcomes of thumb CMC joint surgery. Long-term follow-up over years would be of interest to assess pain, function, and procedure-related adverse events. The only published RCT of SBS specified at least 2 years of follow-up for inclusion in the analysis.\(^7\) Both immediate operative complications and longer-term adverse events would be of interest.
One proposed advantage of SBS over LRTI is a reduction in the occurrence of subsidence (the collapse or settling of bone located immediately next to an implantable device). However, there is no consensus on how to measure subsidence and its correlation to symptoms is not clear.

### Table 1. Outcome Measures

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Measure</th>
<th>Scale Description and Administration</th>
<th>Minimal Clinically Important Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain</td>
<td>Visual analog scale</td>
<td>0-10, Lower score means reduced pain</td>
<td>1.4, 1.6-1.9 points</td>
</tr>
<tr>
<td>Pain and function</td>
<td>Disabilities of the Arm, Shoulder and Hand (DASH)</td>
<td>A 30 Item self-reported questionnaire that measures an individuals' ability to complete tasks, absorb forces and severity of symptoms. Lower scores indicate better functional outcomes.</td>
<td>11-15 points</td>
</tr>
<tr>
<td>Pain and function</td>
<td>Disabilities of the Arm, Shoulder and Hand Questionnaire, QuickDASH</td>
<td>Abbreviated version of DASH (11 items)</td>
<td>16-20 points</td>
</tr>
<tr>
<td>Revision Surgery rates</td>
<td>Frequency, percent</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Surgical Complications</td>
<td>Frequency, percent</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

### Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Consistent with a ‘best available evidence approach,’ within each category of study design, studies with larger sample sizes and longer durations were sought.
- Studies with duplicative or overlapping populations were excluded.

### Review of Evidence

#### Systematic Reviews

Wininger et al (2022) published a systematic review of LRTI compared to SBS for carpometacarpal joint osteoarthritis, with searches conducted through November 2020. Study eligibility criteria included reporting of postoperative DASH or QuickDASH scores. The quality of the overall body of evidence for each intervention was rated for quality, quantity, and consistency using Strength of Recommendation Taxonomy (SORT) criteria.

The analysis included 31 studies (LRTI: 25 studies [1289 thumbs]; SBS: 6 studies [113 thumbs]). At the time the review was conducted, no studies directly comparing SBS to LRTI had been published. The body of evidence for SBS was rated SORT C (based on case series) and for LRTI was rated SORT B (based on inconsistent or limited-quality patient-oriented evidence). In studies that reported both pre-operative and post-operative data, DASH or QuickDash scores improved following either LRTI and SBS. Grip strength and key pinch were similarly improved but inconsistently reported across studies. Overall, complications occurred in 12.3% of 740 individuals who underwent LRTI and 13.3% of 113 who underwent SBS. There were 6 re-operations in the LRTI studies (of which 4 came from RCTs) and 2 re-operations in the SBS studies. Complete reporting of complications varied greatly between studies and follow-up times were generally short, precluding any conclusions on long-term complications associated with each procedure.
The authors noted multiple limitations of the body of the evidence, including increased risk of bias especially for SBS studies, short follow-up times, and lack of reporting of the time period of postoperative outcome measurements. They concluded that, although both LRTI and SBS seemed to provide improved short-term patient-reported functional improvement and objective strength, larger prospectively designed studies of high-quality evidence are needed to determine whether a difference exists between the 2 techniques.

Randomized Controlled Trial
Morais et al (2022) reported on an RCT, conducted at a single center in Portugal that evaluated SBS for thumb CRC joint osteoarthritis (Table 2). The trial compared trapeziectomy with SBS to trapeziectomy with LRTI in 76 individuals. Mean followup was 37.3 months (standard deviation [SD], 12.6) months in the SBS group and 40.5 (SD 14.8) months in the SBS group. Pain and function as assessed by visual analogue scale (VAS) and QuickDash scores at followup improved from baseline in both intervention groups but did not differ between groups (Table 3). The incidence of postoperative complications was also similar in each group. One individual in the SBS and 2 in the LRTI group required reoperation. Of note, 2 individuals in the SBS group and 1 in the LRTI group developed a complex regional pain syndrome requiring physical therapy.

The trial had several important limitations (Tables 4 and 5). Lack of blinding combined with subjective outcome measures poses a serious risk of bias. Outcomes were not prespecified and the trial was not registered. Although the methods section mentions that a power calculation was conducted, no details are given and there is no reporting of pre-specified thresholds for minimally clinically important differences. Generalizability is limited because the trial was conducted at a single center, with all surgeries performed by the same individual. Additionally, 20% of individuals who received surgery were excluded from the analysis. Individuals who were lost to followup (n=5), those who underwent revision surgery (n=7), and those who received associated procedures (n=7) were all classified as ineligible and were not included in the analysis. There was no analysis to account for missing data.

Table 2. Randomized Controlled Trial of Suture Button Suspensionplasty for Thumb Carpometacarpal Joint Osteoarthritis: Characteristics

<table>
<thead>
<tr>
<th>Study; Trial</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morais et al (2022)</td>
<td>Portugal</td>
<td>1</td>
<td>2015-2019</td>
<td>Individuals with thumb carpometacarpal osteoarthritis 9.2% stage II; 64.5% stage III; 26.3% stage IV</td>
<td>39</td>
</tr>
</tbody>
</table>

LRTI: ligament reconstruction and tendon interposition; SBS: suture button suspensionplasty.

Table 3. Randomized Controlled Trial of Suture Button Suspensionplasty for Thumb Carpometacarpal Joint Osteoarthritis: Results

<table>
<thead>
<tr>
<th>Study</th>
<th>Percent of Patients Reporting Pain Relief (SD)</th>
<th>Patient-Reported VAS score at discharge (SD)</th>
<th>Quick DASH score at discharge (SD)</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morais et al (2022)</td>
<td>76</td>
<td>76</td>
<td>76</td>
<td>76</td>
</tr>
<tr>
<td>Study</td>
<td>Percent of Patients Reporting Pain Relief (SD)</td>
<td>Patient-Reported VAS score at discharge (SD)</td>
<td>Quick DASH score at discharge (SD)</td>
<td>Complications</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------------------------</td>
<td>----------------------------------------------</td>
<td>-----------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>SBS</td>
<td>94.6%</td>
<td>1.5 (1.4)</td>
<td>31.6 (20.3)</td>
<td>Postoperative complications (all): 4/37 (11%); Reoperation rate: 1/37 (2.7%)</td>
</tr>
<tr>
<td>LRTI</td>
<td>92.3%</td>
<td>1.3 (1.2)</td>
<td>30.1 (17.8)</td>
<td>Postoperative complications (all): 3/39 (8%); Reoperation rate: 2/39 (5.1%)</td>
</tr>
<tr>
<td>P-value</td>
<td></td>
<td></td>
<td></td>
<td>.6877; .9658; .7336</td>
</tr>
</tbody>
</table>

LRTI: ligament reconstruction and tendon interposition; SBS: suture button suspensionplasty; SD: standard deviation; VAS: visual analog scale.

### Table 4. Study Relevance Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Duration of Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morais et al (2022)&lt;sup&gt;7&lt;/sup&gt;</td>
<td>3. 9.2% of participants had stage 2 osteoarthritis 4. Participants were treated at a single center in Portugal; subpopulations not reported</td>
<td>5. Clinically significant differences not specified</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

- Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.
- Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.
- Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.
- Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

### Table 5. Study Design and Conduct Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocation</th>
<th>Blinding</th>
<th>Selective Reporting</th>
<th>Data Completeness</th>
<th>Power</th>
<th>Statistical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morais et al (2022)&lt;sup&gt;7&lt;/sup&gt;</td>
<td>3. Not described</td>
<td>1. Participants and surgeon not blinded; 1 surgeon performed all procedures</td>
<td>1. Trial not registered; outcomes not pre-specified; clinically</td>
<td>1. 19/95 individuals who received surgery (20%) were</td>
<td>1. Methods section states that a power analysis was performed</td>
<td>3. Methods section notes that confidence intervals were</td>
</tr>
</tbody>
</table>
Study | Allocation<sup>a</sup> | Blinding<sup>b</sup> | Selective Reporting<sup>c</sup> | Data Completeness<sup>d</sup> | Power<sup>e</sup> | Statistical<sup>f</sup> |
--- | --- | --- | --- | --- | --- | --- |
2. outcome assessor described as independent, but not clear if blinded | 2. important differences on outcomes not pre-specified. | excluded: Participants who were lost to follow-up (n = 5), had associated procedures (n=7), underwent revision surgeries (n =4), or refused to participate (n =3) were all defined as not meeting inclusion criteria; no analysis to account for missing data. | but no details | calculated, but none reported in results | 4. No calculation of comparative treatment effects |

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias; 5. Other.

<sup>b</sup> Blinding key: 1. Participants or study staff not blinded; 2. Outcome assessors not blinded; 3. Outcome assessed by treating physician; 4. Other.

<sup>c</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication; 4. Other.

<sup>d</sup> Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials); 7. Other.

<sup>e</sup> Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference; 4. Other.

<sup>f</sup> Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated; 5. Other.

**Nonrandomized Studies**

**Prospective Cohort Study**

Shonuga et al (2023) conducted a prospective cohort study of 112 consecutive individuals who underwent SBS or LRTI (Table 6). Individuals who underwent SBS had significantly lower QuickDASH scores at 1 year postoperatively compared with those who underwent LRTI (Table 7). The 14-point difference between groups exceeded the minimum clinically important difference (MCID) prespecified by the study investigators; however there was no rationale provided for this threshold, and other researchers have recommended a MCID of 16 to 20 points on the QuickDash. No fractures or reoperations occurred in either group. No details on other complications or adverse events are reported. Study limitations are shown in Tables 8 and 9. Lack of blinding and randomization pose a serious risk of bias. Additional limitations are the relatively short-term followup period and variation in the surgical procedures used in the LRTI group.
Table 6. Prospective Cohort Study of Suture Button Suspensionplasty for Thumb Carpometacarpal Joint Osteoarthritis: Characteristics

<table>
<thead>
<tr>
<th>Study</th>
<th>Study Type</th>
<th>Country</th>
<th>Dates</th>
<th>Participants</th>
<th>Trapeziectomy with SBS</th>
<th>Trapeziectomy with LRTI</th>
<th>Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shonuga et al (2023)(^{10})</td>
<td>Prospective Cohort</td>
<td>US</td>
<td>2015-2017</td>
<td>112 consecutive individuals with Eaton stage 3-4 thumb CMC arthritis who underwent open trapeziectomy and suspensionplasty.</td>
<td>n = 59</td>
<td>n = 53</td>
<td>1 year</td>
</tr>
</tbody>
</table>

Exclusions: history of rheumatoid arthritis, previous thumb surgery, traumatic arthritis, or incomplete radiographic records
71.4% female
Mean age 63 years (range 44-80)
Race not reported

LRTI: ligament reconstruction and tendon interposition; SBS: suture button suspensionplasty

Table 7. Prospective Cohort Study of Suture Button Suspensionplasty for Thumb Carpometacarpal Joint Osteoarthritis: Results

<table>
<thead>
<tr>
<th>Study</th>
<th>QuickDASH Questionnaire Score at 12 months</th>
<th>VAS for pain Score at 12 months</th>
<th>Lateral Pinch Strength</th>
<th>Post-Operative Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shonuga et al (2023)(^{10})</td>
<td>SBS 7.5</td>
<td>0.3</td>
<td>5.7 kg</td>
<td>No fractures or reoperations in either group; no additional details</td>
</tr>
<tr>
<td>LRTI</td>
<td>21.5</td>
<td>0.6</td>
<td>5.2 kg</td>
<td></td>
</tr>
<tr>
<td>P-value</td>
<td>&lt;.05</td>
<td>&lt;.05</td>
<td>&lt;.99</td>
<td></td>
</tr>
</tbody>
</table>

LRTI: ligament reconstruction and tendon interposition; SBS: suture button suspensionplasty; VAS: visual analog scale

Table 8. Study Relevance Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Population*</th>
<th>Intervention*</th>
<th>Comparator*</th>
<th>Outcomes*</th>
<th>Duration of Follow-up*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shonuga et al (2023)(^{10})</td>
<td>5. LRTI procedure used FCR or APL tendon, may be differences in outcomes based on variation in procedures</td>
<td>3. Limited detail on adverse events; unclear if outcomes prespecified</td>
<td>1.2. 1-year followup may be insufficient to assess outcomes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

APL: abductor pollicis longus; FCR: flexor carpi radialis; LRTI: ligament reconstruction and tendon interposition.
The study limitations stated in this table are those notable in the current review; this is not a comprehensive
gaps assessment.

- Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.
- Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.
- Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.
- Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

Table 9. Study Design and Conduct Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocation</th>
<th>Blinding</th>
<th>Selective Reporting</th>
<th>Data Completeness</th>
<th>Power</th>
<th>Statistical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shonuga et al (2023)</td>
<td>not randomized</td>
<td>not blinded</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

- Blinding key: 1. Participants or study staff not blinded; 2. Outcome assessors not blinded; 3. Outcome assessed by treating physician; 4. Other.
- Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials); 7. Other.
- Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference; 4. Other.
- Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated; 5. Other.

Retrospective Studies

Multiple retrospective, non-randomized studies have been published. These studies are limited by their lack of a comparator, lack of blinded outcome assessment, outcome assessment based on medical record data, and insufficient follow-up duration to assess longer-term outcomes. Because of their methodological limitations they are not discussed further, but are cited for reference only.

Section Summary: Suture Button Suspensionplasty Fixation System for Thumb Osteoarthritis

The evidence includes a systematic review, 1 RCT, 1 prospective, comparative observational study, and multiple nonrandomized, retrospective studies. Relevant outcomes are symptoms, functional outcomes, and adverse events. A single-center RCT compared trapeziectomy with SBS to trapeziectomy with LRTI in 76 individuals. The RCT had multiple methodologic limitations, including lack of blinding, inappropriate handling of missing data, and no pre-specification of outcome measures. Pain and functional outcomes did not differ between intervention groups after 40 months of follow-up, although operative and recovery time was shorter in the suspensionplasty group. A prospective cohort study of 112 consecutive individuals who underwent suture button suspensionplasty or LRTI found similar improvements in pain scores and function with both procedures, but was limited by a lack of blinding and randomization. Retrospective studies reported improvements in pain and function but have been published but are limited by their design. Additionally, multiple surgical techniques to treat thumb CMC joint osteoarthritis have been developed but there is currently no consensus on the optimal approach, limiting conclusions that can be drawn from comparative studies.
Supplemental Information
The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American College of Rheumatology/Arthritis Foundation
In 2019, the American College of Rheumatology/Arthritis Foundation published a guideline on the management of osteoarthritis of the hand, hip, and knee. The guideline included recommendations for non-surgical treatment of thumb carpometacarpal (CMC) joint osteoarthritis, but surgical approaches were not addressed.

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 10.

Table 10. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT05111405</td>
<td>A Randomized Prospective Multicenter Study Comparing Suture Button Suspensionplasty (SBS) With Ligament Reconstruction and Tendon Interposition (LRTI)</td>
<td>138</td>
<td>May 2025</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

References


**Documentation for Clinical Review**

- No records required

**Coding**

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy.

The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases.
Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>12/01/2023</td>
<td>New policy.</td>
</tr>
</tbody>
</table>

Definitions of Decision Determinations

**Medically Necessary:** Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member’s illness, injury, or disease.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

Prior Authorization Requirements and Feedback (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member’s health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member’s eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at [www.blueshieldca.com/provider](http://www.blueshieldca.com/provider).

We are interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California or Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration.
Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.
### POLICY STATEMENT

<table>
<thead>
<tr>
<th>BEFORE</th>
<th>AFTER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>New Policy</strong></td>
<td><strong>Suture Button Suspensionplasty Fixation System for Thumb Carpometacarpal Osteoarthritis 7.01.176</strong></td>
</tr>
</tbody>
</table>
| **Policy Statement:** N/A | **Policy Statement:**  
I. Suture button suspensionplasty for thumb carpometacarpal joint osteoarthritis is considered *investigational*. |